
    
      This is a randomized, double-blind, placebo-controlled, single ascending IV dose study
      conducted at one study center in the United States. Safety will be assessed throughout the
      study and serial blood samples and urine samples will be collected for the safety and
      pharmacokinetic assessment of GMI-1359.
    
  